Get the Stockscreener App
3.15
0.64%
0.02
After Hours:
3.21
0.06
+1.90%
Compass Therapeutics Inc stock is traded at $3.15, with a volume of 1.24M.
It is up +0.64% in the last 24 hours and up +43.84% over the past month.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
See More
Previous Close:
$3.13
Open:
$3.15
24h Volume:
1.24M
Relative Volume:
1.51
Market Cap:
$435.59M
Revenue:
-
Net Income/Loss:
$-45.44M
P/E Ratio:
-9.00
EPS:
-0.35
Net Cash Flow:
$-42.28M
1W Performance:
+10.53%
1M Performance:
+43.84%
6M Performance:
+21.15%
1Y Performance:
+205.83%
1-Day Range:
$3.10
$3.27
1-Week Range:
$2.635
$3.27
52-Week Range:
$0.8741
$4.08
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
3.15 | 394.11M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Apr-02-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Why Compass Therapeutics Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser
What makes Compass Therapeutics Inc. stock price move sharplyPro Trader Stock Focus - Newser
How Compass Therapeutics Inc. stock performs during market volatilityBreakout Level Watch - Newser
Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Stifel reiterates Buy rating on Compass Therapeutics stock with $11 target - Investing.com Canada
Contrasting Compass Therapeutics (NASDAQ:CMPX) & Generation Bio (NASDAQ:GBIO) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of “Buy” by Brokerages - Defense World
Compass Therapeutics (CMPX) soars 4.01% on FDA Fast Track Designation - AInvest
Vontobel Holding Ltd. Invests $57,000 in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics: Promising Clinical Trials and Strategic Confidence Earn Buy Rating - AInvest
Compass Therapeutics (NASDAQ:CMPX) Upgraded at Raymond James Financial - Defense World
Compass Therapeutics, Inc.(NasdaqCM:CMPX) added to Russell Small Cap Comp Growth Index - MarketScreener
PD-1 and PD-L1 Inhibitors Competitor Landscape Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Compass Therapeutics, Aurigene Discovery Tech - The Globe and Mail
SG Americas Securities LLC Buys 545,767 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Acquired by Bank of America Corp DE - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Sells 48,021 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics Confirms Directors at Annual Meeting - TipRanks
Cholangiocarcinoma Market Booming Worldwide, Estimated to Reach USD 2,334.4 Mn by 2032 | Incyte CorporationSOUTHEAST - SOUTHEAST - NEWS CHANNEL NEBRASKA
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Squarepoint Ops LLC Acquires New Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
CMPX to Participate in Virtual Meeting Hosted by Piper Sandler | - GuruFocus
CMPX to Participate in Virtual Meeting Hosted by Piper Sandler | CMPX Stock News - GuruFocus
Two Sigma Advisers LP Cuts Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Transition Metals (CVE:XTM) Shares Up 62.5% – Time to Buy? - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Purchased by Two Sigma Advisers LP - Defense World
BNP Paribas Financial Markets Makes New $27,000 Investment in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
ProShare Advisors LLC Has $42,000 Position in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Northern Trust Corp Sells 43,164 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics, Inc. (CMPX) Stock Analysis: A Biotech Gem with Over 500% Potential Upside - DirectorsTalk Interviews
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Insider Buying: Thomas Schuetz Acquires Additional Shares of Com - GuruFocus
Compass Therapeutics CEO acquires $21,100 in common stock - Investing.com Australia
Compass Therapeutics CEO acquires $21,100 in common stock By Investing.com - Investing.com India
Compass Therapeutics CEO Acquires 10,000 Shares - TradingView
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of “Buy” from Brokerages - Defense World
Dimensional Fund Advisors LP Buys New Stake in Babcock & Wilcox Enterprises, Inc. (NYSE:BW) - Defense World
Bell Investment Advisors Inc Buys 79 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
Dark Forest Capital Management LP Cuts Stock Holdings in NVIDIA Co. (NASDAQ:NVDA) - Defense World
Price T Rowe Associates Inc. MD Increases Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Bought by Price T Rowe Associates Inc. MD - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by Price T Rowe Associates Inc. MD - Defense World
Ceera Investments LLC Grows Stock Position in Apple Inc. (NASDAQ:AAPL) - Defense World
Apple Inc. (NASDAQ:AAPL) is Sound View Wealth Advisors Group LLC’s Largest Position - Defense World
Frontier Asset Management LLC Acquires 1,041 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
Rebalance LLC Grows Stake in Apple Inc. (NASDAQ:AAPL) - Defense World
Ocugen, Inc. (NASDAQ:OCGN) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Voya Investment Management LLC Sells 5,102 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Spotlight On Three Promising Penny Stocks In May 2025 - Yahoo Finance
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Wells Fargo & Company MN - Defense World
Wells Fargo & Company MN Acquires 13,038 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):